Ligand Pharmaceuticals (LGND) Cash & Equivalents (2010 - 2026)

Ligand Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $115.1 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 139.8% year-over-year to $115.1 million; the TTM figure through Mar 2026 stood at $115.1 million (up 139.8% YoY), while the FY2025 annual figure was $174.9 million, up 141.92% from the prior year.
• Cash & Equivalents came in at $115.1 million for Q1 2026 at Ligand Pharmaceuticals, down from $174.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $174.9 million in Q4 2025 to a low of $4.1 million in Q3 2022.
• A 5-year average of $57.5 million and a median of $48.0 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 82.43% in 2022 and soared 491.8% in 2023, its largest moves.
• Ligand Pharmaceuticals' Cash & Equivalents stood at $45.0 million in 2022, then slumped by 49.0% to $23.0 million in 2023, then soared by 215.01% to $72.3 million in 2024, then jumped by 141.92% to $174.9 million in 2025, then tumbled by 34.21% to $115.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $115.1 million, $174.9 million, and $139.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison